PT - JOURNAL ARTICLE AU - Di Liu AU - Jingyun Yang AU - Bowen Feng AU - Wenjin Lu AU - Chuntao Zhao AU - Lizhuo Li TI - Mendelian randomization analysis identified genes pleiotropically associated with the risk and prognosis of COVID-19 AID - 10.1101/2020.09.02.20187179 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.02.20187179 4099 - http://medrxiv.org/content/early/2020/09/04/2020.09.02.20187179.short 4100 - http://medrxiv.org/content/early/2020/09/04/2020.09.02.20187179.full AB - Objectives COVID-19 has caused a large global pandemic. Patients with COVID-19 exhibited considerable variation in disease behavior. Pervious genome-wide association studies have identified potential genetic variants involved in the risk and prognosis of COVID-19, but the underlying biological interpretation remains largely unclear.Methods We applied the summary data-based Mendelian randomization (SMR) method to identify genes that were pleiotropically associated with the risk and various outcomes of COVID-19, including severe respiratory confirmed COVID-19 and hospitalized COVID-19.Results In blood, we identified 2 probes, ILMN_1765146 and ILMN_1791057 tagging IFNAR2, that showed pleiotropic association with hospitalized COVID-19 (β [SE] = 0.42 [0.09], P = 4.75×10−06 and β [SE] = –0.48 [0.11], P = 6.76×10−06, respectively). Although no other probes were significant after correction for multiple testing in both blood and lung, multiple genes as tagged by the top 5 probes were involved in inflammation or antiviral immunity, and several other tagged genes, such as PON2 and HPS5, were involved in blood coagulation.Conclusions We identified IFNAR2 and other potential genes that could be involved in the susceptibility or prognosis of COVID-19. These findings provide important leads to a better understanding of the mechanisms of cytokine storm and venous thromboembolism in COVID-19 and potential therapeutic targets for the effective treatment of COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDr. Lizhuo Li's research was supported by the National Natural Science Foundation of China (Grant No. 81660329). The study was supported by NIH/NIA grants P30AG10161, R01AG15819, R01AG17917, R01AG36042, U01AG61356 and 1RF1AG064312-01. Di Liu was supported by China Scholarship Council (CSC 201908110339). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We use the summary statistics in the public domain.This is not available.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analyzed during this study are included in this published article and its supplementary information files.